左西孟旦治疗心力衰竭临床研究新进展

New Clinical Research Progress of Levosimendan in the Treatment of Heart Failure

心力衰竭是各种心血管疾病发展的最后阶段,是大多数器质性心脏病进展的最终结局,也是最主要的死亡原因.左西孟旦作为一种新型钙离子增敏剂,作用机制独特,具有增加心肌收缩力、扩张血管,能有效地改善心力衰竭患者的血流动力学障碍,并且不增加心肌耗氧量,不影响心肌舒张功能,也不增加恶性心律失常的风险,同时具有抑制心室重塑的作用.现有多项临床研究均证实,左西孟旦可明显改善心力衰竭患者的临床症状、稳定血流动力学指标、明显降低病死率,但对于心力衰竭患者的远期预后,目前研究得出了不同的结果.

Heart failure is the final stage of the development of various cardiovascular diseases, is the ultimate ending of the most organic heart diseases progression, and also is the main cause of death. As a new type of calcium sensiti-zation agent, levosimendan has a unique function, which can strengthen myocardium contractile force, dilate blood vessel and improve the hemodynamic problem for the patients suffering from heart failure obviously. Levosimendan does not increase myocardial oxygen consumption, neither influence diastolic function, nor add the risk of malignant arrhythmia. Meanwhile, it has the function of suppressing ventricular remodeling. Many existing clinical studies have confirmed that levosimendan can improve clinical symptoms in patients with heart failure effectively, steady the he-modynamics and reduce mortality. But there obtained different research results in regard of the long-term prognosis of patients with heart failure.